Alza Corporation

Diane E Nedberge

Robert M Gale

Linda E Atkinson

Su Il Yum

Eun Soo Lee

David J Enscore

Patricia S Campbell

Felix A Landrau

Yu-Ling Cheng

Linda M Hearney

Richard D Frame

Harold M Leeper

Melinda K Nelson

Lina T Taskovich

Edna Sugihara

Shari B Libicki

The present invention comprises a composition comprising a matrix (,) adapted to be placed in drug- and permeation-enhancing mixture-transmitting relation to a selected skin (,) or other body site. The matrix (,) contains sufficient amounts of drug, permeation enhancer(s) and poly-N-vinyl amide to continuously administer to the site, the drug, in a therapeutically effective amount, and the permeation-enhancing mixture, in an amount effective to enhance the permeation of the skin (,) to the drug, the device (,) shows increased transdermal flux as compared to the transdermal flux of the drug from a device (,) containing no poly-N-vinyl amide. Incorporating poly-N-vinyl amide into the transdermal system also improves the adhesion and stability of the system.

Incorporating poly-N-vinly amide in a transdermal system

An improved process for manufacturing transdermal drug delivery devices and devices made therefrom. The invention provides a heat equilibration process for the manufacture of drug delivery devices which eliminates the need to preload the body contacting layer with a drug. The method has particular application in the manufacture of transdermal drug delivery devices including a drug reservoir comprising drug in excess of saturation.

Drug delivery devices and process of manufacture

Incorporating poly-N-vinyl amide in a transdermal system

Skin permeation enhancer compositions using glycerol monolinoleate

The present invention provides compositions and methods for the transdermal administration of a contraceptively effective amount of gestodene and estrogen, such as ethinyl estradiol, in combination, together with a suitable permeation enhancer. The amount of the estrogen codelivered is kept at an about constant and contraceptively effective rate while the amount of gestogen codelivered varies depending on the phase of the menstrual cycle but remains at a contraceptively effective rate. The size of the system may also vary depending on the amount of gestogeno be delivered.

Transdermal contraceptive formulations methods and devices

The present invention is directed to the transdermal administration of oxybutynin together with a suitable permeation enhancer. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in oxybutynin- and permeation enhancer-transmitting relation with the skin site. The matrix contains sufficient amounts of a permeation enhancer and of oxybutynin, in combination, to continuously administer to the skin for a predetermined period of time the oxybutynin to provide an effective therapeutic result. The invention is also directed to a method for the transdermal administration of a therapeutically effective amount of oxybutynin together with a skin permeation-enhancing amount of a suitable permeation enhancer.

Transdermal administration of oxybutynin

The present invention provides compositions and methods for the transdermal administration of a contraceptively effective amount of gestodene and an estrogen, such as ethinyl estradiol, in combination, together with a suitable permeation enhancer.

Transdermal contraceptive formulations, methods and devices

The present invention provides compositions and methods for the transdermal administration of a therapeutically effective amount of a synthetic 19-nor-progesterone (ST-1435) together with, optionally, a suitable permeation enhancer.

Transdermal delivery of the gestogen ST-1435 and devices therefor

The present invention provides compositions and methods for the transdermal administration of a therapeutically effective amount of a synthetic 19-nor-progesterone (ST-1435) and an estrogen, in combination, together with, optionally, a suitable permeation enhancer.

Transdermal formulations, methods and devices

The present invention provides compositions and methods for the transdermal administration of a contraceptively effective amount of a synthetic 19-nor-progesterone (ST-1435) and an estrogen, in combination, together with a suitable permeation enhancer.

A transdermal delivery system for the administering of ethinyl estradiol and levonorgestrel, in combination, utilizing a polymer matrix having the drug formulation along with a permeation enhancer dispersed throughout.

Transdermal contraceptive formulations

A transdermal delivery system for the administering of progesterone and an estradiol ester alone or in combination utilizing a polymer matrix having the drug(s) along with a permeation enhancer dispersed throughout.

Growing community of inventors

Los Altos, CA, United States of America

Diane E Nedberge